$Pfizer(PFE.US) has been consolidating in the $23-$25 range for a while, with the 200-day SMA at $25.75 on 5/15, almost a solid resistance. However, it closed at $26.21 today, up 1.4 points, and rose further to $26.23 after-hours, marking the second consecutive trading day above the 200-day moving average. Technical analysts might read this as a "deep test + first effective breakout," but I'm more focused on why it managed to hold above this time.

The news clues from the past month are quite clear:

5/20 The company announced Phase II interim data for its pneumococcal vaccine, showing "stronger immune response than the current vaccine";

5/22 Trump publicly praised Pfizer and Eli Lilly for building factories in the US;

5/26 FDA advisory committee prepares to review whether the 2026-27 seasonal COVID vaccine needs to be updated to target the XFG variant;

5/27 New anti-infective drug formulation breakthrough + company webcast.

These four positive factors combined have gradually digested the trapped positions below the 200-day line.

Catalysts to watch in the next 1-2 months:

First, the FDA's decision on the 2026-27 COVID vaccine variant update (Pfizer's Comirnaty is among the first to benefit once the XFG variant is confirmed).

Second, the complete Phase II data for the pneumococcal vaccine + the timing for entering Phase III. The marginal impact of this product on Pfizer's valuation is estimated to be around $1-2 EPS in analyst models.

Third, the Trump administration may offer tax incentives or procurement priority to pharmaceutical companies building factories in the US, representing a policy-driven long-tail alpha.

I believe holding above the 200-day line is not the end but the beginning. $26 is the first resistance level, and $28 is the true pivot since the 2024 pullback. In the short term, I'll watch for a week—if PFE doesn't fall below $25.75 in the next 5 trading days, I'll test the waters with a 1/3 position. If it breaks below, I'll exit without holding on stubbornly—once a pharmaceutical stock loses its 200-day line, it often takes another 1-2 months of consolidation.